Apretude, the New Tool in the HIV Prevention Toolkit - Managed Healthcare Executive

Long-acting injectable holds advantages over daily pills for pre-exposure prophylaxis against HIV, says ViiV executive.

There is significant unmet need in HIV prevention, with less than 1 in 4 of the 1.2 million people who could benefit from re-exposure prophylaxis (PrEP) in the U.S. currently taking it despite its wi… [+2776 chars]

full article...